PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
2549054-1	1989	A tetrapeptide Arg-Gly-Asp-Ser (RGDS) has been shown to be a versatile cell recognition signal of extracellular matrix components for the interaction with cells.	arginyl-glycyl-aspartyl-serine	15-30	ral guanine nucleotide dissociation stimulator	Homo sapiens	32-36
2783136-1	1989	The effects of the fibrinogen-derived tetrapeptide, Arg-Gly-Asp-Ser (RGDS), on platelet activation processes was studied.	arginyl-glycyl-aspartyl-serine	52-67	ral guanine nucleotide dissociation stimulator	Homo sapiens	69-73
2535276-9	1989	Indirect evidence for a possible role of fibronectin in EC adhesion to type-IV collagen is given by the ability of the tetrapeptide (Arg-Gly-Asp-Ser (10 micrograms) to temporarily block (15-30 min) the adhesion-promoting effect of type-IV collagen.	arginyl-glycyl-aspartyl-serine	133-148	fibronectin 1	Bos taurus	41-52
2472429-7	1989	A synthetic peptide containing the Arg-Gly-Asp-Ser (RGDS) sequence also inhibited monocyte adherence to fibronectin.	arginyl-glycyl-aspartyl-serine	35-50	fibronectin 1	Homo sapiens	104-115
2544438-7	1989	It was found that (i) cell migration on FN-coated surfaces was specifically inhibited by anti-FN receptor antibody P1F8 but not by anticollagen receptor antibody P1H5; (ii) the migration was strongly inhibited by Arg-Gly-Asp-Ser but not by other oligopeptide sequences.	arginyl-glycyl-aspartyl-serine	213-228	fibronectin 1	Homo sapiens	40-42
2544438-7	1989	It was found that (i) cell migration on FN-coated surfaces was specifically inhibited by anti-FN receptor antibody P1F8 but not by anticollagen receptor antibody P1H5; (ii) the migration was strongly inhibited by Arg-Gly-Asp-Ser but not by other oligopeptide sequences.	arginyl-glycyl-aspartyl-serine	213-228	fibronectin 1	Homo sapiens	94-96
2539213-4	1989	At 1 n mol/L alpha-thrombin or 25 nmol/L gamma-thrombin, platelet fibrinogen was expressed on the surface of the cells notwithstanding the presence of AP-2, a monoclonal antibody to the glycoprotein (GP) IIb-IIIa complex, or the synthetic peptides Arg-Gly-Asp-Ser and gamma 400-411, all substances that prevented the binding of plasma fibrinogen to platelets.	arginyl-glycyl-aspartyl-serine	248-263	fibrinogen beta chain	Homo sapiens	66-76
2521665-6	1989	Arg-Gly-Asp-Ser inhibited the binding of fibronectin to PMNs, strongly suggesting that the fibronectin receptor is one of the Arg-Gly-Asp receptor family.	arginyl-glycyl-aspartyl-serine	0-15	fibronectin 1	Homo sapiens	41-52
2521665-6	1989	Arg-Gly-Asp-Ser inhibited the binding of fibronectin to PMNs, strongly suggesting that the fibronectin receptor is one of the Arg-Gly-Asp receptor family.	arginyl-glycyl-aspartyl-serine	0-15	fibronectin 1	Homo sapiens	91-102
3196604-1	1988	The possibility of using the synthetic tetrapeptide arginine-glycine-aspartic acid-serine (Arg-Gly-Asp-Ser, RGDS), which was recently identified as the common cell attachment site of adhesive plasma proteins, for platelet preservation during cardiopulmonary bypass (CPB) was investigated.	arginyl-glycyl-aspartyl-serine	91-106	ral guanine nucleotide dissociation stimulator	Homo sapiens	108-112
3265160-3	1988	The receptor complex, named integrin, binds to fibronectin by recognition of a specific peptide sequence, Arg-Gly-Asp-Ser (RGDS), in the fibronectin molecule (Pierschbacher and Ruoslahti, Proc Natl Acad Sci USA 81:5985-5988, 1984).	arginyl-glycyl-aspartyl-serine	106-121	fibronectin 1	Gallus gallus	47-58
3265160-3	1988	The receptor complex, named integrin, binds to fibronectin by recognition of a specific peptide sequence, Arg-Gly-Asp-Ser (RGDS), in the fibronectin molecule (Pierschbacher and Ruoslahti, Proc Natl Acad Sci USA 81:5985-5988, 1984).	arginyl-glycyl-aspartyl-serine	106-121	fibronectin 1	Gallus gallus	137-148
3319626-8	1987	Both adhesion on pFn as well as formation of stress fibers in the presence of TPA could be prevented by the synthetic peptide Arg-Gly-Asp-Ser (RGDS).	arginyl-glycyl-aspartyl-serine	126-141	ral guanine nucleotide dissociation stimulator	Homo sapiens	143-147
2965651-3	1988	In addition, a monoclonal antibody against a 15-kDa fragment of Fn containing the Arg-Gly-Asp-Ser (RGDS) sequence and several polyclonal monospecific mouse antibodies against a synthetic RGDS peptide also recognized the above two molecules.	arginyl-glycyl-aspartyl-serine	82-97	ral guanine nucleotide dissociation stimulator	Mus musculus	99-103
2965651-3	1988	In addition, a monoclonal antibody against a 15-kDa fragment of Fn containing the Arg-Gly-Asp-Ser (RGDS) sequence and several polyclonal monospecific mouse antibodies against a synthetic RGDS peptide also recognized the above two molecules.	arginyl-glycyl-aspartyl-serine	82-97	ral guanine nucleotide dissociation stimulator	Mus musculus	187-191
3334894-2	1988	Because with human platelets the cell adhesion peptide, Arg-Gly-Asp-Ser (RGDS), inhibits aggregation and the binding of 125I-fibrinogen to ADP-stimulated platelets, its effects on rabbit and rat platelets were studied to investigate the differences in the fibrinogen requirements of platelets from the three species.	arginyl-glycyl-aspartyl-serine	56-71	ral guanine nucleotide dissociation stimulator	Homo sapiens	73-77
3334894-2	1988	Because with human platelets the cell adhesion peptide, Arg-Gly-Asp-Ser (RGDS), inhibits aggregation and the binding of 125I-fibrinogen to ADP-stimulated platelets, its effects on rabbit and rat platelets were studied to investigate the differences in the fibrinogen requirements of platelets from the three species.	arginyl-glycyl-aspartyl-serine	56-71	fibrinogen beta chain	Homo sapiens	125-135
3338818-2	1988	By contrast, inclusion of the tetrapeptide fibrinogen antagonist, Arg-Gly-Asp-Ser(RGDS), inhibited both intermediate and near-maximal, but not threshold, levels of platelet activation stimulated by AggCRP.	arginyl-glycyl-aspartyl-serine	66-81	fibrinogen beta chain	Homo sapiens	43-53
3338818-2	1988	By contrast, inclusion of the tetrapeptide fibrinogen antagonist, Arg-Gly-Asp-Ser(RGDS), inhibited both intermediate and near-maximal, but not threshold, levels of platelet activation stimulated by AggCRP.	arginyl-glycyl-aspartyl-serine	66-81	ral guanine nucleotide dissociation stimulator	Homo sapiens	82-86
2948581-2	1987	The adhesion could be quantitatively inhibited by the synthetic peptide Arg-Gly-Asp-Ser (RGDS) and upon hemin-induced differentiation or trypsinization of the cells.	arginyl-glycyl-aspartyl-serine	72-87	ral guanine nucleotide dissociation stimulator	Homo sapiens	89-93
3025221-2	1986	Several striking differences were found in the sensitivity of the two cell types to inhibition by a series of synthetic peptides modeled on the Arg-Gly-Asp-Ser (RGDS) tetrapeptide adhesion signal.	arginyl-glycyl-aspartyl-serine	144-159	ral guanine nucleotide dissociation stimulator	Homo sapiens	161-165
33673496-3	2021	To improve cell vitality, cell-adhesive Arg-Gly-Asp-Ser (RGDS) peptide is immobilized on the N-(gamma-maleimidobutyryloxy)succinimide-activated P(HEMA-AEMA) hydrogels via reaction of SH with maleimide groups.	arginyl-glycyl-aspartyl-serine	40-55	ral guanine nucleotide dissociation stimulator	Mus musculus	57-61
3009364-1	1986	The core of the fibronectin cell-attachment site has been shown to be the tetrapeptide sequence Arg-Gly-Asp-Ser (RGDS).	arginyl-glycyl-aspartyl-serine	96-111	fibronectin 1	Homo sapiens	16-27
3009364-1	1986	The core of the fibronectin cell-attachment site has been shown to be the tetrapeptide sequence Arg-Gly-Asp-Ser (RGDS).	arginyl-glycyl-aspartyl-serine	96-111	ral guanine nucleotide dissociation stimulator	Homo sapiens	113-117
3741254-5	1986	A synthetic tetrapeptide, arg-gly-asp-ser (RGDS), derived from the FN cell-binding domain, has been shown to interfere with attachment of some cell types.	arginyl-glycyl-aspartyl-serine	26-41	ral guanine nucleotide dissociation stimulator	Homo sapiens	43-47
3741254-5	1986	A synthetic tetrapeptide, arg-gly-asp-ser (RGDS), derived from the FN cell-binding domain, has been shown to interfere with attachment of some cell types.	arginyl-glycyl-aspartyl-serine	26-41	fibronectin 1	Homo sapiens	67-69
3903025-2	1985	The active site of the Fn molecule has been identified as a four-amino acid sequence, arg-gly-asp-ser (RGDS), located on each monomer of the cell-binding domain.	arginyl-glycyl-aspartyl-serine	86-101	ral guanine nucleotide dissociation stimulator	Homo sapiens	103-107
2995350-8	1985	Arg-Gly-Asp-Ser, but not Arg-Gly-Tyr-Ser-Leu-Gly, also inhibited fibrinogen binding to ADP-stimulated platelets.	arginyl-glycyl-aspartyl-serine	0-15	fibrinogen beta chain	Homo sapiens	65-75
2995350-9	1985	This inhibition was competitive with a Ki of approximately equal to 25 microM but was incomplete even at higher tetrapeptide concentrations, indicating that Arg-Gly-Asp-Ser is a partial competitive inhibitor of fibrinogen binding.	arginyl-glycyl-aspartyl-serine	157-172	fibrinogen beta chain	Homo sapiens	211-221
3160809-2	1985	The activation of C3 receptors by Fn was mediated by a receptor that recognizes a sequence, Arg-Gly-Asp-Ser (RGDS), present in the cell-binding domain of Fn.	arginyl-glycyl-aspartyl-serine	92-107	fibronectin 1	Homo sapiens	34-36
3160809-2	1985	The activation of C3 receptors by Fn was mediated by a receptor that recognizes a sequence, Arg-Gly-Asp-Ser (RGDS), present in the cell-binding domain of Fn.	arginyl-glycyl-aspartyl-serine	92-107	ral guanine nucleotide dissociation stimulator	Homo sapiens	109-113
3160809-2	1985	The activation of C3 receptors by Fn was mediated by a receptor that recognizes a sequence, Arg-Gly-Asp-Ser (RGDS), present in the cell-binding domain of Fn.	arginyl-glycyl-aspartyl-serine	92-107	fibronectin 1	Homo sapiens	154-156
32350965-6	2020	Pharmacological targeting of integrin beta8 by Arg-Gly-Asp-Ser efficiently suppressed the sustained growth and drugs resistance in bladder cancer cells.	arginyl-glycyl-aspartyl-serine	47-62	integrin subunit beta 8	Homo sapiens	29-43
32786732-6	2020	The peptides Arg-Gly-Asp-Ser (RGDS) and Arg-Glu-Asp-Val (REDV) were chosen as cell-recognition ligands and were attached to an adapter DNA (aDNA), which can specifically bind to the dG3 moiety through G-quadruplex formation.	arginyl-glycyl-aspartyl-serine	13-28	ral guanine nucleotide dissociation stimulator	Mus musculus	30-34
32786732-6	2020	The peptides Arg-Gly-Asp-Ser (RGDS) and Arg-Glu-Asp-Val (REDV) were chosen as cell-recognition ligands and were attached to an adapter DNA (aDNA), which can specifically bind to the dG3 moiety through G-quadruplex formation.	arginyl-glycyl-aspartyl-serine	13-28	Larval cuticle protein	Drosophila melanogaster	182-185
32262602-6	2015	To enhance the efficiency of gene transfection, the Arg-Gly-Asp-Ser (RGDS) peptide was immobilized on the silver nanoparticles.	arginyl-glycyl-aspartyl-serine	52-67	ral guanine nucleotide dissociation stimulator	Homo sapiens	69-73
31043333-8	2019	To determine in vivo effects, burn wounds of rats were treated with the bioactive Arg-Gly-Asp-Ser (RGDS)-modified gel that showed greater cell proliferation in vitro.	arginyl-glycyl-aspartyl-serine	82-97	ral guanine nucleotide dissociation stimulator	Rattus norvegicus	99-103
31252450-4	2019	The resultant alkyne-containing PHEMA was then used to modify the azide-terminated oligopeptides [Arg-Gly-Asp-Ser (RGDS)] with a photolabile 3-amino-3-(2-nitrophenyl)propanoic acid moiety via the copper-catalyzed alkyne-azide click chemistry.	arginyl-glycyl-aspartyl-serine	98-113	ral guanine nucleotide dissociation stimulator	Mus musculus	115-119
28972000-6	2017	We constructed an extracellular matrix-mimicking PA nanomatrix gel (PA-RGDS) by incorporating the cell adhesive ligand Arg-Gly-Asp-Ser (RGDS) and a matrix metalloproteinase-2-degradable sequence.	arginyl-glycyl-aspartyl-serine	119-134	ral guanine nucleotide dissociation stimulator	Homo sapiens	71-75
28972000-6	2017	We constructed an extracellular matrix-mimicking PA nanomatrix gel (PA-RGDS) by incorporating the cell adhesive ligand Arg-Gly-Asp-Ser (RGDS) and a matrix metalloproteinase-2-degradable sequence.	arginyl-glycyl-aspartyl-serine	119-134	ral guanine nucleotide dissociation stimulator	Homo sapiens	136-140
31121097-1	2019	SpyCatcher, a 15 kDa protein domain that spontaneously forms a site-specific covalent bond with the 13 amino acid peptide SpyTag, was used to covalently link a model recombinant protein containing a SpyCatcher domain and the adhesive ligand Arg-Gly-Asp-Ser (RGDS) (RGDS-SC) into SpyTag-containing poly(ethylene glycol) (PEG) hydrogels.	arginyl-glycyl-aspartyl-serine	241-256	ral guanine nucleotide dissociation stimulator	Homo sapiens	258-262
31121097-1	2019	SpyCatcher, a 15 kDa protein domain that spontaneously forms a site-specific covalent bond with the 13 amino acid peptide SpyTag, was used to covalently link a model recombinant protein containing a SpyCatcher domain and the adhesive ligand Arg-Gly-Asp-Ser (RGDS) (RGDS-SC) into SpyTag-containing poly(ethylene glycol) (PEG) hydrogels.	arginyl-glycyl-aspartyl-serine	241-256	ral guanine nucleotide dissociation stimulator	Homo sapiens	265-269
21679959-4	2011	The following immobilizations of cell repulsive poly(ethylene glycol) after the first illumination and cell adhesive sequence Arg-Gly-Asp-Ser (RGDS) after the second illumination on the surface helped create surface heterogeneity.	arginyl-glycyl-aspartyl-serine	126-141	ral guanine nucleotide dissociation stimulator	Mus musculus	143-147
26301301-3	2015	Here VEGF-siRNA/RGDS/nanodiamond was prepared by conjugating Arg-Gly-Asp-Ser (RGDS) and VEGF-siRNA to nanodiamond delivery particles.	arginyl-glycyl-aspartyl-serine	61-76	vascular endothelial growth factor A	Homo sapiens	5-9
26301301-3	2015	Here VEGF-siRNA/RGDS/nanodiamond was prepared by conjugating Arg-Gly-Asp-Ser (RGDS) and VEGF-siRNA to nanodiamond delivery particles.	arginyl-glycyl-aspartyl-serine	61-76	ral guanine nucleotide dissociation stimulator	Homo sapiens	16-20
26301301-3	2015	Here VEGF-siRNA/RGDS/nanodiamond was prepared by conjugating Arg-Gly-Asp-Ser (RGDS) and VEGF-siRNA to nanodiamond delivery particles.	arginyl-glycyl-aspartyl-serine	61-76	ral guanine nucleotide dissociation stimulator	Homo sapiens	78-82
20216924-6	2010	Gradients of a cell-adhesion ligand, Arg-Gly-Asp-Ser (RGDS), was incorporated in the poly(ethylene glycol)-diacrylate (PEG-DA) hydrogels to test the response of endothelial cells.	arginyl-glycyl-aspartyl-serine	37-52	ral guanine nucleotide dissociation stimulator	Homo sapiens	54-58
19864017-6	2010	The blockage of Arg-Gly-Asp (RGD) specific platelet receptors using an Arg-Gly-Asp-Ser (RGDS) peptide led to significant inhibition of platelet adhesion to adsorbed Alb, with the extent of inhibition and morphology of adherent platelets being similar for both Alb and Fg.	arginyl-glycyl-aspartyl-serine	71-86	ral guanine nucleotide dissociation stimulator	Homo sapiens	88-92
19864017-6	2010	The blockage of Arg-Gly-Asp (RGD) specific platelet receptors using an Arg-Gly-Asp-Ser (RGDS) peptide led to significant inhibition of platelet adhesion to adsorbed Alb, with the extent of inhibition and morphology of adherent platelets being similar for both Alb and Fg.	arginyl-glycyl-aspartyl-serine	71-86	albumin	Homo sapiens	165-168
19864017-6	2010	The blockage of Arg-Gly-Asp (RGD) specific platelet receptors using an Arg-Gly-Asp-Ser (RGDS) peptide led to significant inhibition of platelet adhesion to adsorbed Alb, with the extent of inhibition and morphology of adherent platelets being similar for both Alb and Fg.	arginyl-glycyl-aspartyl-serine	71-86	albumin	Homo sapiens	260-263
17697986-0	2007	Evaluation of L929 fibroblast attachment and proliferation on Arg-Gly-Asp-Ser (RGDS)-immobilized chitosan in serum-containing/serum-free cultures.	arginyl-glycyl-aspartyl-serine	62-77	ral guanine nucleotide dissociation stimulator	Mus musculus	79-83
17647223-4	2008	As the following stage, adhesive peptides Arg-Gly-Asp-Ser (RGDS) were grafted into the backbone of DL-PLA by using carbodiimide as a coupling agent, in order to endow DL-PLA with bioactivity and biospecificity.	arginyl-glycyl-aspartyl-serine	42-57	ral guanine nucleotide dissociation stimulator	Homo sapiens	59-63
17982091-7	2007	Moreover, treatment with anti-alpha(v), anti-beta(3), or Arg-Gly-Asp-Ser (RGDS), inhibited LPS-induced NF-kappaB activation.	arginyl-glycyl-aspartyl-serine	57-72	ral guanine nucleotide dissociation stimulator	Mus musculus	74-78
17982091-7	2007	Moreover, treatment with anti-alpha(v), anti-beta(3), or Arg-Gly-Asp-Ser (RGDS), inhibited LPS-induced NF-kappaB activation.	arginyl-glycyl-aspartyl-serine	57-72	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	103-112
17825222-1	2007	AIM: To study the effect of Arg-Gly-Asp-Ser (RGDS) tetrapeptide on the expression of matrix metalloproteinase-13 (MMP-13) and the tissue inhibitor of metalloproteinase-1(TIMP-1) in hepatic stellate cell(HSC) stimulated by fibronectin (FN).	arginyl-glycyl-aspartyl-serine	28-43	ral guanine nucleotide dissociation stimulator	Homo sapiens	45-49
17825222-1	2007	AIM: To study the effect of Arg-Gly-Asp-Ser (RGDS) tetrapeptide on the expression of matrix metalloproteinase-13 (MMP-13) and the tissue inhibitor of metalloproteinase-1(TIMP-1) in hepatic stellate cell(HSC) stimulated by fibronectin (FN).	arginyl-glycyl-aspartyl-serine	28-43	matrix metallopeptidase 13	Homo sapiens	85-112
17825222-1	2007	AIM: To study the effect of Arg-Gly-Asp-Ser (RGDS) tetrapeptide on the expression of matrix metalloproteinase-13 (MMP-13) and the tissue inhibitor of metalloproteinase-1(TIMP-1) in hepatic stellate cell(HSC) stimulated by fibronectin (FN).	arginyl-glycyl-aspartyl-serine	28-43	matrix metallopeptidase 13	Homo sapiens	114-120
17825222-1	2007	AIM: To study the effect of Arg-Gly-Asp-Ser (RGDS) tetrapeptide on the expression of matrix metalloproteinase-13 (MMP-13) and the tissue inhibitor of metalloproteinase-1(TIMP-1) in hepatic stellate cell(HSC) stimulated by fibronectin (FN).	arginyl-glycyl-aspartyl-serine	28-43	fibronectin 1	Homo sapiens	222-233
17825222-1	2007	AIM: To study the effect of Arg-Gly-Asp-Ser (RGDS) tetrapeptide on the expression of matrix metalloproteinase-13 (MMP-13) and the tissue inhibitor of metalloproteinase-1(TIMP-1) in hepatic stellate cell(HSC) stimulated by fibronectin (FN).	arginyl-glycyl-aspartyl-serine	28-43	fibronectin 1	Homo sapiens	235-237
17697986-1	2007	In this study, chitosan membranes prepared by the solvent casting method were modified with the Arg-Gly-Asp-Ser (RGDS) sequence of fibronectin using the photochemical immobilization technique.	arginyl-glycyl-aspartyl-serine	96-111	ral guanine nucleotide dissociation stimulator	Mus musculus	113-117
17697986-1	2007	In this study, chitosan membranes prepared by the solvent casting method were modified with the Arg-Gly-Asp-Ser (RGDS) sequence of fibronectin using the photochemical immobilization technique.	arginyl-glycyl-aspartyl-serine	96-111	fibronectin 1	Mus musculus	131-142
17293376-8	2007	The fibronectin-induced depression of contractility was blocked by the integrin antagonist Arg-Gly-Asp-Ser (RGDS) but not by its negative control Gly-Arg-Ala-Asp-Ser-Pro (GRADSP).	arginyl-glycyl-aspartyl-serine	91-106	fibronectin 1	Bos taurus	4-15
15901596-8	2005	Cofilin is normally rephosphorylated when platelets are stimulated in the presence of Arg-Gly-Asp-Ser (RGDS) peptide or wortmannin to block alpha(IIb)beta3 cross-linking and signaling or in platelets isolated from a patient with Glanzmann thrombasthenia, which express only 2-3% of normal alpha(IIb)beta3 levels.	arginyl-glycyl-aspartyl-serine	86-101	cofilin 1	Homo sapiens	0-7
17346130-4	2007	A potent peptide is Arg-Gly-Asp-Ser (RGDS) and its derivatives in various forms.	arginyl-glycyl-aspartyl-serine	20-35	ral guanine nucleotide dissociation stimulator	Homo sapiens	37-41
17173745-1	2006	OBJECTIVE: To investigate the efficacy and feasibility of RGDS (Arg-Gly-Asp-Ser) peptide (an alpha(nu)-integrin antagonist) in a rat model of laser-induced choroidal neovascularization (CNV).	arginyl-glycyl-aspartyl-serine	64-79	ral guanine nucleotide dissociation stimulator	Rattus norvegicus	58-62
16669788-11	2006	Arg-Gly-Asp-Ser inhibited beta3, Src and Akt phosphorylation and sensitized polyamine-depleted cells to tumour necrosis factor alpha/cycloheximide-mediated apoptosis.	arginyl-glycyl-aspartyl-serine	0-15	SRC proto-oncogene, non-receptor tyrosine kinase	Rattus norvegicus	33-36
16669788-11	2006	Arg-Gly-Asp-Ser inhibited beta3, Src and Akt phosphorylation and sensitized polyamine-depleted cells to tumour necrosis factor alpha/cycloheximide-mediated apoptosis.	arginyl-glycyl-aspartyl-serine	0-15	AKT serine/threonine kinase 1	Rattus norvegicus	41-44
16420189-0	2006	Synthesis of a precursor dipeptide of RGDS (Arg-Gly-Asp-Ser) catalysed by the industrial protease alcalase.	arginyl-glycyl-aspartyl-serine	44-59	ral guanine nucleotide dissociation stimulator	Homo sapiens	38-42
16420189-1	2006	Synthesis of Bz-Arg-Gly-NH(2) (N-benzoylargininylglycinamide) [a precursor dipeptide of RGDS (Arg-Gly-Asp-Ser)] catalysed by protease in water/organic co-solvent systems was studied.	arginyl-glycyl-aspartyl-serine	94-109	ral guanine nucleotide dissociation stimulator	Homo sapiens	88-92
15958305-2	2005	METHODS: The targeted microbubbles were prepared by coupling Arg-Gly-Asp-Ser (RGDS) with the lipid microbubbles, which were added to the microthrombus generated by platelet aggregation.	arginyl-glycyl-aspartyl-serine	61-76	ral guanine nucleotide dissociation stimulator	Homo sapiens	78-82
14531798-9	2003	The internalization by HUVECs was mediated by actin polymerization, and it was inhibited by RGDS (Arg-Gly-Asp-Ser) tetrapeptide, antihuman fibronectin and antihuman integrin beta1 monoclonal antibodies.	arginyl-glycyl-aspartyl-serine	98-113	ral guanine nucleotide dissociation stimulator	Mus musculus	92-96
10997555-5	2000	Treatment with Arg-Gly-Asp-Ser (RGDS) and rhodostomin effectively suppressed the TGF-beta1-enhanced adhesion activity to fibronectin and type I collagen.	arginyl-glycyl-aspartyl-serine	15-30	ral guanine nucleotide dissociation stimulator	Rattus norvegicus	32-36
12824296-3	2003	We analyzed the effect of a RGD-containing peptide, as Arg-Gly-Asp-Ser (RGDS), on the regulation of TGF-beta1 secretion in cultured human mesangial cells.	arginyl-glycyl-aspartyl-serine	55-70	transforming growth factor beta 1	Homo sapiens	100-109
12939181-1	2003	OBJECTIVES: To investigate the effects of Arg-Gly-Asp-Ser (RGDS) tetrapeptide on integrin signaling and apoptosis in fibronectin (FN) -stimulated hepatic stellate cells (HSCs).	arginyl-glycyl-aspartyl-serine	42-57	ral guanine nucleotide dissociation stimulator	Homo sapiens	59-63
12939181-1	2003	OBJECTIVES: To investigate the effects of Arg-Gly-Asp-Ser (RGDS) tetrapeptide on integrin signaling and apoptosis in fibronectin (FN) -stimulated hepatic stellate cells (HSCs).	arginyl-glycyl-aspartyl-serine	42-57	fibronectin 1	Homo sapiens	117-128
12939181-1	2003	OBJECTIVES: To investigate the effects of Arg-Gly-Asp-Ser (RGDS) tetrapeptide on integrin signaling and apoptosis in fibronectin (FN) -stimulated hepatic stellate cells (HSCs).	arginyl-glycyl-aspartyl-serine	42-57	fibronectin 1	Homo sapiens	130-132
12639933-5	2003	Activation of glomerulosa cells with Arg-Gly-Asp-Ser (RGDS) induced an increase in [Ca(2+)](i), whereas fibronectin triggered a release of Ca(2+) from InsP(3)-sensitive Ca(2+) stores.	arginyl-glycyl-aspartyl-serine	37-52	ral guanine nucleotide dissociation stimulator	Rattus norvegicus	54-58
11719373-4	2001	A similar inhibition of aggregation to 4N1-1 was obtained in the presence of Arg-Gly-Asp-Ser in mouse platelets deficient in FcR gamma chain or SLP-76 and in patients with type I Glanzmann thrombasthenia.	arginyl-glycyl-aspartyl-serine	77-92	Fc receptor, IgE, high affinity I, gamma polypeptide	Mus musculus	125-134
10884507-3	2000	The antiplatelet effect of MB3 was about 300 times more potent than those of TA-993 and a glycoprotein IIb/IIIa receptor antagonist, Arg-Gly-Asp-Ser (RGDS).	arginyl-glycyl-aspartyl-serine	133-148	ral guanine nucleotide dissociation stimulator	Homo sapiens	150-154
10997555-5	2000	Treatment with Arg-Gly-Asp-Ser (RGDS) and rhodostomin effectively suppressed the TGF-beta1-enhanced adhesion activity to fibronectin and type I collagen.	arginyl-glycyl-aspartyl-serine	15-30	transforming growth factor, beta 1	Rattus norvegicus	81-90
10997555-5	2000	Treatment with Arg-Gly-Asp-Ser (RGDS) and rhodostomin effectively suppressed the TGF-beta1-enhanced adhesion activity to fibronectin and type I collagen.	arginyl-glycyl-aspartyl-serine	15-30	fibronectin 1	Rattus norvegicus	121-132
9863654-10	1998	The tetrapeptide Arg-Gly-Asp-Ser (RGDS; 20-200 microM) which inhibits von Willebrand factor, fibrinogen and fibronectin-mediated adhesion, had no effect on the promoting effect of platelets on tube formation.	arginyl-glycyl-aspartyl-serine	17-32	fibrinogen beta chain	Homo sapiens	93-103
10072774-2	1999	Cells of the B. glabrata embryonic (Bge) snail cell line were initially tested for their sensitivity to the integrin-specific tetrapeptide inhibitor Arg-Gly-Asp-Ser (RGDS).	arginyl-glycyl-aspartyl-serine	149-164	ral guanine nucleotide dissociation stimulator	Homo sapiens	166-170
9863654-10	1998	The tetrapeptide Arg-Gly-Asp-Ser (RGDS; 20-200 microM) which inhibits von Willebrand factor, fibrinogen and fibronectin-mediated adhesion, had no effect on the promoting effect of platelets on tube formation.	arginyl-glycyl-aspartyl-serine	17-32	fibronectin 1	Homo sapiens	108-119
11324534-0	1998	[Effect of Arg-Gly-Asp-Ser (RGDS) peptide on ADP-induced signal transduction of activated rat platelet].	arginyl-glycyl-aspartyl-serine	11-26	ral guanine nucleotide dissociation stimulator	Rattus norvegicus	28-32
9417058-6	1998	Both the vitronectin-induced MMP-2 production and vitronectin-enhanced invasion were blocked by the peptide ligand Arg-Gly-Asp-Ser (RGDS).	arginyl-glycyl-aspartyl-serine	115-130	vitronectin	Mus musculus	9-20
9417058-6	1998	Both the vitronectin-induced MMP-2 production and vitronectin-enhanced invasion were blocked by the peptide ligand Arg-Gly-Asp-Ser (RGDS).	arginyl-glycyl-aspartyl-serine	115-130	matrix metallopeptidase 2	Mus musculus	29-34
9417058-6	1998	Both the vitronectin-induced MMP-2 production and vitronectin-enhanced invasion were blocked by the peptide ligand Arg-Gly-Asp-Ser (RGDS).	arginyl-glycyl-aspartyl-serine	115-130	vitronectin	Mus musculus	50-61
9417058-6	1998	Both the vitronectin-induced MMP-2 production and vitronectin-enhanced invasion were blocked by the peptide ligand Arg-Gly-Asp-Ser (RGDS).	arginyl-glycyl-aspartyl-serine	115-130	ral guanine nucleotide dissociation stimulator	Mus musculus	132-136
11324534-1	1998	The purpose of this work was to investigate the effect of Arg-Gly-Asp-Ser (RGDS) peptide on platelet aggregation, protein phosphorylation, protein kinase C (PKC) and mitogen-activated protein kinase (MAPK) activity during platelet activation.	arginyl-glycyl-aspartyl-serine	58-73	ral guanine nucleotide dissociation stimulator	Rattus norvegicus	75-79
10923408-0	1998	[Effects of Arg-Gly-Asp-Ser (RGDS) tetrapeptide on apoptosis-related genes in glomerular mesangial cells].	arginyl-glycyl-aspartyl-serine	12-27	ral guanine nucleotide dissociation stimulator	Homo sapiens	29-33
10923408-1	1998	OBJECTIVE: To investigate the effects of Arg-Gly-Asp-Ser (RGDS) tetrapeptide on the expressions of apoptosis-related genes interleukin-1 beta-converting enzyme (ICE) and bcl-2 in human glomerular mesangial cells, so as to provide experimental evidence for regulating proliferation and apoptosis of mesangial cells with RGD-containing polypeptide.	arginyl-glycyl-aspartyl-serine	41-56	ral guanine nucleotide dissociation stimulator	Homo sapiens	58-62
10923408-1	1998	OBJECTIVE: To investigate the effects of Arg-Gly-Asp-Ser (RGDS) tetrapeptide on the expressions of apoptosis-related genes interleukin-1 beta-converting enzyme (ICE) and bcl-2 in human glomerular mesangial cells, so as to provide experimental evidence for regulating proliferation and apoptosis of mesangial cells with RGD-containing polypeptide.	arginyl-glycyl-aspartyl-serine	41-56	caspase 1	Homo sapiens	123-159
10923408-1	1998	OBJECTIVE: To investigate the effects of Arg-Gly-Asp-Ser (RGDS) tetrapeptide on the expressions of apoptosis-related genes interleukin-1 beta-converting enzyme (ICE) and bcl-2 in human glomerular mesangial cells, so as to provide experimental evidence for regulating proliferation and apoptosis of mesangial cells with RGD-containing polypeptide.	arginyl-glycyl-aspartyl-serine	41-56	caspase 1	Homo sapiens	161-164
10923408-1	1998	OBJECTIVE: To investigate the effects of Arg-Gly-Asp-Ser (RGDS) tetrapeptide on the expressions of apoptosis-related genes interleukin-1 beta-converting enzyme (ICE) and bcl-2 in human glomerular mesangial cells, so as to provide experimental evidence for regulating proliferation and apoptosis of mesangial cells with RGD-containing polypeptide.	arginyl-glycyl-aspartyl-serine	41-56	BCL2 apoptosis regulator	Homo sapiens	170-175
16793677-9	1997	Surprisingly arginyl-glycyl aspartyl serine (RGDS) inhibited the formation of both types of conjugate but this may be because it also inhibited both platelet and leukocyte activation as measured by CD62P and CD11b exposure and/or interferes with the binding of adhesion molecules other than fibrinogen.	arginyl-glycyl-aspartyl-serine	13-43	ral guanine nucleotide dissociation stimulator	Homo sapiens	45-49
9046103-7	1997	Arg-Gly-Asp-Ser (RGDS) containing peptides inhibited adhesion of cells differentially, according to substratum; no dependence on extent of progation in vitro was observed.	arginyl-glycyl-aspartyl-serine	0-15	ral guanine nucleotide dissociation stimulator	Rattus norvegicus	17-21
9358311-4	1997	Addition of the tetrapeptide Arg-Gly-Asp-Ser (RGDS) inhibited cell adhesion onto fibronectin-immobilized films while cell adhesion onto polyallylamine-immobilized films was not inhibited by RGDS.	arginyl-glycyl-aspartyl-serine	29-44	ral guanine nucleotide dissociation stimulator	Homo sapiens	46-50
9358311-4	1997	Addition of the tetrapeptide Arg-Gly-Asp-Ser (RGDS) inhibited cell adhesion onto fibronectin-immobilized films while cell adhesion onto polyallylamine-immobilized films was not inhibited by RGDS.	arginyl-glycyl-aspartyl-serine	29-44	fibronectin 1	Homo sapiens	81-92
16793677-9	1997	Surprisingly arginyl-glycyl aspartyl serine (RGDS) inhibited the formation of both types of conjugate but this may be because it also inhibited both platelet and leukocyte activation as measured by CD62P and CD11b exposure and/or interferes with the binding of adhesion molecules other than fibrinogen.	arginyl-glycyl-aspartyl-serine	13-43	selectin P	Homo sapiens	198-203
16793677-9	1997	Surprisingly arginyl-glycyl aspartyl serine (RGDS) inhibited the formation of both types of conjugate but this may be because it also inhibited both platelet and leukocyte activation as measured by CD62P and CD11b exposure and/or interferes with the binding of adhesion molecules other than fibrinogen.	arginyl-glycyl-aspartyl-serine	13-43	integrin subunit alpha M	Homo sapiens	208-213
16793677-9	1997	Surprisingly arginyl-glycyl aspartyl serine (RGDS) inhibited the formation of both types of conjugate but this may be because it also inhibited both platelet and leukocyte activation as measured by CD62P and CD11b exposure and/or interferes with the binding of adhesion molecules other than fibrinogen.	arginyl-glycyl-aspartyl-serine	13-43	fibrinogen beta chain	Homo sapiens	291-301
9031466-5	1997	Moreover, inhibition of normal platelet aggregation with the tetrapeptide arg-gly-asp-ser (RGDS) which impairs fibrinogen binding to integrin alpha IIb beta 3, did not alter significantly SHP-1 phosphorylation.	arginyl-glycyl-aspartyl-serine	74-89	ral guanine nucleotide dissociation stimulator	Homo sapiens	91-95
8582015-3	1995	Hybrids of fibronectin-related peptides [Arg-Gly-Asp (RGD), Arg-Gly-Asp-Ser (RGDS)] and poly(ethylene glycol) (PEG) were prepared and their inhibitory effects on experimental metastasis in mice were examined.	arginyl-glycyl-aspartyl-serine	60-75	fibronectin 1	Mus musculus	11-22
9772661-1	1996	AIM: To study the effects of Arg-Gly-Asp-Ser (RGDS), a synthetic short peptide of fibrinogen degradation, on the Ca2+ transport function of cardiac sarcoplasmic reticulum in rat septic shock.	arginyl-glycyl-aspartyl-serine	29-44	ral guanine nucleotide dissociation stimulator	Rattus norvegicus	46-50
8787788-0	1995	Antimetastatic activities of synthetic Arg-Gly-Asp-Ser (RGDS) and Arg-Leu-Asp-Ser (RLDS) peptide analogues and their inhibitory mechanisms.	arginyl-glycyl-aspartyl-serine	39-54	ral guanine nucleotide dissociation stimulator	Mus musculus	56-60
7667835-4	1995	At 234 microM, the tetrapeptide Arg-Gly-Asp-Ser (RGDS) suppressed platelet aggregation by 74%, reduced force at 1200 s by 45% and reduced gel elastic modulus by 19%.	arginyl-glycyl-aspartyl-serine	32-47	ral guanine nucleotide dissociation stimulator	Homo sapiens	49-53
8747597-1	1995	A new compound containing the cell-adhesive Arg-Gly-Asp-Ser (RGDS) peptide was synthesized, i.e. tetrahydrofurantetracarboxylic acid (THFTCA)-RGDS conjugate [THFTCA- (RGDS)3, FC-243], and the inhibitory effect of FC-243 on lung metastasis of B16-BL6 melanoma in mice was examined in combination with or without the anticancer agent doxorubicin (DOX).	arginyl-glycyl-aspartyl-serine	44-59	ral guanine nucleotide dissociation stimulator	Mus musculus	61-65
8747597-1	1995	A new compound containing the cell-adhesive Arg-Gly-Asp-Ser (RGDS) peptide was synthesized, i.e. tetrahydrofurantetracarboxylic acid (THFTCA)-RGDS conjugate [THFTCA- (RGDS)3, FC-243], and the inhibitory effect of FC-243 on lung metastasis of B16-BL6 melanoma in mice was examined in combination with or without the anticancer agent doxorubicin (DOX).	arginyl-glycyl-aspartyl-serine	44-59	ral guanine nucleotide dissociation stimulator	Mus musculus	142-146
8747597-1	1995	A new compound containing the cell-adhesive Arg-Gly-Asp-Ser (RGDS) peptide was synthesized, i.e. tetrahydrofurantetracarboxylic acid (THFTCA)-RGDS conjugate [THFTCA- (RGDS)3, FC-243], and the inhibitory effect of FC-243 on lung metastasis of B16-BL6 melanoma in mice was examined in combination with or without the anticancer agent doxorubicin (DOX).	arginyl-glycyl-aspartyl-serine	44-59	ral guanine nucleotide dissociation stimulator	Mus musculus	142-146
8438902-3	1993	Incubation of sickle RBC with monoclonal antibodies against platelet surface receptors GPIb or GPIIb/IIIa, or with the integrin receptor agonist Arg-Gly-Asp-Ser (RGDS) decreased the ULvWF-mediated sickle RBC adhesion to EC 84%, > 99%, and 90%, respectively.	arginyl-glycyl-aspartyl-serine	145-160	ral guanine nucleotide dissociation stimulator	Homo sapiens	162-166
8128439-8	1993	of the anti-adhesive tetrapeptide Arg-Gly-Asp-Ser (RGDS) showed only a slight effect on thrombus formation whereas aspirin was ineffective.	arginyl-glycyl-aspartyl-serine	34-49	ral guanine nucleotide dissociation stimulator	Rattus norvegicus	51-55
8222396-0	1993	Inhibition of tumor metastasis by Arg-Gly-Asp-Ser (RGDS) peptide conjugated with sulfated chitin derivative, SCM-chitin-RGDS.	arginyl-glycyl-aspartyl-serine	34-49	ral guanine nucleotide dissociation stimulator	Mus musculus	51-55
8222396-0	1993	Inhibition of tumor metastasis by Arg-Gly-Asp-Ser (RGDS) peptide conjugated with sulfated chitin derivative, SCM-chitin-RGDS.	arginyl-glycyl-aspartyl-serine	34-49	ral guanine nucleotide dissociation stimulator	Mus musculus	120-124
8222396-1	1993	We have synthesized a new compound in which Arg-Gly-Asp-Ser (RGDS) was conjugated with 6-O-sulfated and 6-O-carboxymethyl-chitin (SCM-chitin), i.e. SCM-chitin-RGDS, and tested the inhibitory effect on lung and liver metastases of three different types of tumors in mice.	arginyl-glycyl-aspartyl-serine	44-59	ral guanine nucleotide dissociation stimulator	Mus musculus	61-65
8222396-1	1993	We have synthesized a new compound in which Arg-Gly-Asp-Ser (RGDS) was conjugated with 6-O-sulfated and 6-O-carboxymethyl-chitin (SCM-chitin), i.e. SCM-chitin-RGDS, and tested the inhibitory effect on lung and liver metastases of three different types of tumors in mice.	arginyl-glycyl-aspartyl-serine	44-59	ral guanine nucleotide dissociation stimulator	Mus musculus	159-163
8287052-1	1993	Synthetic peptide analogues of the Arg-Gly-Asp-Ser (RGDS) sequence of fibronectin in which the amino acid of Gly was substituted with another one, named X, i.e. Arg-X-Asp-Ser (R-X-DS), and N-terminal modified R-X-DS have been synthesized to examine their antimetastatic effects in murine lung or liver metastasis models, as well as the inhibitory effect on tumor cell invasion, migration and adhesion in vitro.	arginyl-glycyl-aspartyl-serine	35-50	ral guanine nucleotide dissociation stimulator	Mus musculus	52-56
8287052-1	1993	Synthetic peptide analogues of the Arg-Gly-Asp-Ser (RGDS) sequence of fibronectin in which the amino acid of Gly was substituted with another one, named X, i.e. Arg-X-Asp-Ser (R-X-DS), and N-terminal modified R-X-DS have been synthesized to examine their antimetastatic effects in murine lung or liver metastasis models, as well as the inhibitory effect on tumor cell invasion, migration and adhesion in vitro.	arginyl-glycyl-aspartyl-serine	35-50	fibronectin 1	Mus musculus	70-81
1717069-3	1991	When platelet aggregation was inhibited by the Arg-Gly-Asp-Ser (RGDS) peptide, thrombin stimulation of whole blood resulted in platelet expression of granule membrane protein 140 (GMP-140) and, simultaneously, a marked increase in the percentage of monocytes and neutrophils (PMN) binding platelets, as well as an increase in the number of platelets bound per monocyte and PMN.	arginyl-glycyl-aspartyl-serine	47-62	ral guanine nucleotide dissociation stimulator	Homo sapiens	64-68
1438206-7	1992	However, isolated alpha IIb beta 3 was able to bind to an Arg-Gly-Asp-Ser affinity column, and binding of soluble fibrinogen to the patient"s platelets could be triggered by modulators of alpha IIb beta 3 conformation such as the Arg-Gly-Asp-Ser peptide and alpha-chymotrypsin.	arginyl-glycyl-aspartyl-serine	230-245	fibrinogen beta chain	Homo sapiens	114-124
1575681-4	1992	When immobilized in the presence of prostaglandin I2 and the fibrinogen antagonist Arg-Gly-Asp-Ser, the platelets adhered less firmly to fibrinogen, and in many [Ca2+]i remained low and constant.	arginyl-glycyl-aspartyl-serine	83-98	fibrinogen beta chain	Homo sapiens	61-71
1575681-4	1992	When immobilized in the presence of prostaglandin I2 and the fibrinogen antagonist Arg-Gly-Asp-Ser, the platelets adhered less firmly to fibrinogen, and in many [Ca2+]i remained low and constant.	arginyl-glycyl-aspartyl-serine	83-98	fibrinogen beta chain	Homo sapiens	137-147
1737795-1	1992	In order to assess the requirement for the Arg-Gly-Asp-Ser (RGDS) consensus adhesion sequence in von Willebrand factor (vWF) for vWF binding to platelets and endothelial cells, point mutations were introduced into this sequence by site-directed mutagenesis.	arginyl-glycyl-aspartyl-serine	43-58	ral guanine nucleotide dissociation stimulator	Homo sapiens	60-64
1737795-1	1992	In order to assess the requirement for the Arg-Gly-Asp-Ser (RGDS) consensus adhesion sequence in von Willebrand factor (vWF) for vWF binding to platelets and endothelial cells, point mutations were introduced into this sequence by site-directed mutagenesis.	arginyl-glycyl-aspartyl-serine	43-58	von Willebrand factor	Homo sapiens	97-118
1737795-1	1992	In order to assess the requirement for the Arg-Gly-Asp-Ser (RGDS) consensus adhesion sequence in von Willebrand factor (vWF) for vWF binding to platelets and endothelial cells, point mutations were introduced into this sequence by site-directed mutagenesis.	arginyl-glycyl-aspartyl-serine	43-58	von Willebrand factor	Homo sapiens	120-123
1737795-1	1992	In order to assess the requirement for the Arg-Gly-Asp-Ser (RGDS) consensus adhesion sequence in von Willebrand factor (vWF) for vWF binding to platelets and endothelial cells, point mutations were introduced into this sequence by site-directed mutagenesis.	arginyl-glycyl-aspartyl-serine	43-58	von Willebrand factor	Homo sapiens	129-132
1717069-3	1991	When platelet aggregation was inhibited by the Arg-Gly-Asp-Ser (RGDS) peptide, thrombin stimulation of whole blood resulted in platelet expression of granule membrane protein 140 (GMP-140) and, simultaneously, a marked increase in the percentage of monocytes and neutrophils (PMN) binding platelets, as well as an increase in the number of platelets bound per monocyte and PMN.	arginyl-glycyl-aspartyl-serine	47-62	coagulation factor II, thrombin	Homo sapiens	79-87
1717069-3	1991	When platelet aggregation was inhibited by the Arg-Gly-Asp-Ser (RGDS) peptide, thrombin stimulation of whole blood resulted in platelet expression of granule membrane protein 140 (GMP-140) and, simultaneously, a marked increase in the percentage of monocytes and neutrophils (PMN) binding platelets, as well as an increase in the number of platelets bound per monocyte and PMN.	arginyl-glycyl-aspartyl-serine	47-62	selectin P	Homo sapiens	150-178
1717069-3	1991	When platelet aggregation was inhibited by the Arg-Gly-Asp-Ser (RGDS) peptide, thrombin stimulation of whole blood resulted in platelet expression of granule membrane protein 140 (GMP-140) and, simultaneously, a marked increase in the percentage of monocytes and neutrophils (PMN) binding platelets, as well as an increase in the number of platelets bound per monocyte and PMN.	arginyl-glycyl-aspartyl-serine	47-62	selectin P	Homo sapiens	180-187
1879434-9	1991	The binding of both the Fg-Au and Ig-Au were inhibited using the tetrapeptide Arg-Gly-Asp-Ser (RGDS) (93% and 98% inhibition, respectively), AP-2 (98% and 97%, respectively) and platelets from patients with Glanzmann"s thrombasthenia (GT) (99% and 98%, respectively).	arginyl-glycyl-aspartyl-serine	78-93	ral guanine nucleotide dissociation stimulator	Homo sapiens	95-99
2211834-4	1990	By comparison, the tetrapeptide Arg-Gly-Asp-Ser (RGDS) inhibited resorption by rat or chicken osteoclasts with an IC50 of 0.1 mM while ala24-echistatin was inactive.	arginyl-glycyl-aspartyl-serine	32-47	ral guanine nucleotide dissociation stimulator	Rattus norvegicus	49-53
2380248-2	1990	Cell adhesion to fibronectin can be mediated by the interaction of an integrin (alpha 5 beta 1) with the Arg-Gly-Asp-Ser (RGDS)-containing cell adhesion region of fibronectin.	arginyl-glycyl-aspartyl-serine	105-120	fibronectin 1	Homo sapiens	17-28
2380248-2	1990	Cell adhesion to fibronectin can be mediated by the interaction of an integrin (alpha 5 beta 1) with the Arg-Gly-Asp-Ser (RGDS)-containing cell adhesion region of fibronectin.	arginyl-glycyl-aspartyl-serine	105-120	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	88-94
2380248-2	1990	Cell adhesion to fibronectin can be mediated by the interaction of an integrin (alpha 5 beta 1) with the Arg-Gly-Asp-Ser (RGDS)-containing cell adhesion region of fibronectin.	arginyl-glycyl-aspartyl-serine	105-120	ral guanine nucleotide dissociation stimulator	Homo sapiens	122-126
2380248-2	1990	Cell adhesion to fibronectin can be mediated by the interaction of an integrin (alpha 5 beta 1) with the Arg-Gly-Asp-Ser (RGDS)-containing cell adhesion region of fibronectin.	arginyl-glycyl-aspartyl-serine	105-120	fibronectin 1	Homo sapiens	163-174